$CYCU

Cycurion Q2 Results: EPS beats estimate, sales miss YoY growth

Cycurion (NASDAQ: CYCU) reported Q2 EPS of $(0.41), beating the $(0.56) consensus, and Q2 revenue of $3.757 million, above the $3.615 million estimate. However, sales fell 3.37% year over year to $3.888 million. The company also said its Nasdaq delisting hearing is set for Aug. 20, 2026.

Original reporting
Published Aug 14, 2026, 2:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 15, 2026, 1:19 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Cycurion Q2 Results: EPS beats estimate, sales miss YoY growth — source image
Decision brief

The 30-second read

$CYCUNeutralMed
01

Why it matters

The quarter shows a sharp EPS loss narrowing alongside modest revenue contraction, while the Nasdaq hearing date keeps a binary delisting risk in focus until the Panel’s final written decision.

02

Market read

Traders get two actionable catalysts: a Q2 EPS beat with YoY revenue decline, and a confirmed Aug 20 Nasdaq hearing that can affect delisting risk and trading liquidity.

03

What to watch

The Nasdaq hearing is a separate catalyst; traders may price in delisting probability and liquidity risk more than the quarter’s operating performance.

Relevance 7/10Novelty 6/10Timing: ahead of Aug 20 Nasdaq Hearings Panel decision

Background

Cycurion is a Nasdaq-listed cybersecurity provider facing an exchange compliance review, with a scheduled hearing before the Nasdaq Hearings Panel on Aug 20, 2026.

Company-level read

Ticker impact

$CYCUNeutralMedium confidence
Context

Cycurion reported Q2 EPS of -$0.41, beating -$0.56 consensus, while sales fell 3.37% YoY to $3.757M.

Expected impact

Near-term volatility likely around earnings interpretation and the upcoming Nasdaq Hearings Panel timeline.

Evidence & confidence

The article provides concrete Q2 EPS and sales figures plus a scheduled Nasdaq hearing date, both of which can drive trading decisions. However, it lacks guidance, cash flow, and delisting outcome details, limiting conviction on magnitude/direction.

Market effects

Cybersecurity small-cap sentiment may hinge on whether cost discipline can offset weak top-line trends.

No clear regional spillover beyond US small-cap tech risk appetite.

Limited, as the news is company-specific (earnings plus Nasdaq compliance process).

Counterpoint

The EPS beat could be driven by one-time items or non-recurring expense reductions, so the market may fade the improvement if revenue weakness persists.

Key entities

  • Cycurion

    NASDAQ-listed cybersecurity solutions provider reporting Q2 results and confirming an Aug 20 Nasdaq Hearings Panel hearing.

  • Nasdaq Hearings Panel

    Exchange body scheduled to issue a final written decision after the Aug 20 hearing.

  • Kevin Kelly

    Chairman and CEO who reiterated focus on the business plan and the Nasdaq process.

Related articles

$CYCUHigh

Why Did CYCU Stock Jump 15% Today?

Cycurion (CYCU) shares rose 15% after announcing a $1M strategic partnership with a Fortune 500 company. The multi-year deal covers AI, security, and support. CYCU stock breached its 50-DMA for the first time since November 2025. The company expects growth and expansion opportunities.

$CYCUHigh

Cycurion shares surge 37% more after $54.6M health IT contract win

Cycurion Inc. (CYCU) shares rose 37% in premarket trading after securing a $54.6M, 10-year contract for health IT modernization, adding to a 496% gain the prior day. The deal is expected to generate over $5M in annual revenue starting November 2026. The company reported a narrowed net loss and improved gross margins in Q1 2026. Analysts maintain a Buy rating with a $7.00 price target. Cycurion also faces a Nasdaq delisting threat for failing to meet the minimum bid price requirement, with a hear

$CYCUHigh

1 as margins hit 29.1%, HHS award signed – Minichart

Cycurion (NASDAQ: CYCU) announced a 1-for-8 reverse stock split to meet NASDAQ requirements. The company reported a gross margin increase to 29.1% and a $54.6M 10-year HHS contract. It also authorized a $500K share repurchase program and aims for profitability by Q2 2027. CEO Kevin Kelly addressed market manipulation allegations.